Clinical Trials and Research News Weekly Roundup | MedinCell’s ‘Mass Roll-out’ of Ivermectin for COVID-19: Study Data Show Promise

MedinCell’s Mission for ‘Mass Roll-out’ of Ivermectin for COVID-19: Early Study Data Points Reveal Promise:
TrialSite News first introduced Montpellier, France-based MedinCell, and their efforts to commercialize an ivermectin-based treatment for COVID-19 back in April. The French biotech company now reports positive first results from a clinical trial aiming at the validating the safety of continuous administration of ivermectin. Presented at an international “Collaborative Workshop—Ivermectin against COVID-19,” MedinCell reports no side effects observed with the first two doses in the study, which totals three doses. And so, they announced via press release that a first long-acting injectable formulation is ready to enter regulatory development. Embracing a prophylactic strategy, the company seeks to mimic the approach taken against HIV: “preexposure prophylaxis” (PrEP) evidencing efficacy as well as the need for long-acting injectable treatments, as the are the only ones that guarantee the continuity of protection. This French company also explores a “postexposure prophylaxis” (PEP) effort for established close contact with COVID-19.


Real-World Retrospective Exposure-Crossover Study of 70K+ Patients Reveals Most Frequent Complications Associated with COVID-19:
A sizable retrospective study involving the University of Buffalo, Aetion, Inc., HealthVerity, Inc. and the University of Toronto confirms a significant number of complications associated with COVID-19. Published in the Canadian Medical Association Journal (CMAJ), the team used de-identified outpatient and inpatient medical claims from American health databases to identify 70,288 patients who were infected with SARS-CoV-2, the virus behind COVID-19. Covering a duration from March 1 to April 30, 2020 over half of the health visits involved hospitalization, with about 5% of the total admitted into intensive care. With a median age of 65 and 55.8% female the authors studied a plethora of medical codes targeting those that increased in number post pandemic onset. Sure enough this real world evidence (RWE)-based study found that the most frequent complications associated with COVID-19 included pneumonia, respiratory failure, kidney failure and sepsis or systemic inflammation. These findings aligned with other observations. Overall, the risk associated with a patient with COVID-19 succumbing to these more serious ailments equaled 27.6% for pneumonia, 22.6% for respiratory failure, 11.8% kidney failure and 10.4% associated with sepsis or systemic inflammation.
Additionally these researchers found other real world evidence, although rare in association with COVID-19, such as a range of other conditions associated with COVID-19 such as collapsed lung, blood clotting disorders and heart inflammation. COVID-19 isn’t associated with a higher risk of stroke according to this study.

 
 

Responses

This site uses Akismet to reduce spam. Learn how your comment data is processed.

  1. RE MedinCell Rollout:

    I’m not sure I see the point of this study or the point of this mysterious injectible drug, other than profit or determining an Ivermectin LDL50. The dosages seem rather massive. Somehow this makes me think of the purposely flawed HCQ studies that gave massive overdoses to the participants, to somehow “prove” HCQ caused arrhythmia and heart valve timing irregularities.

    On the other hand, I am very glad to see another group getting behind Ivermectin.

    We read here, just the other day, about the medical workers in Bangladesh who got a single pill of Ivermectin a month, and this protected 93.1% of them, even when working daily in the Covid wards. This for a drug with such a short half life that it mostly clears the body in about 3 days. The implication is there are long lasting beneficial effects, but the mechanism has not yet been identified.

    Plenty of reports that a single 12mg pill, or one every 3-4 days for a week, seems to work for the mildly to moderately ill. We’ve got the I-MASK+ protocol, based on real world, front line experience, that uses a lighter dosage as a once a week prophylactic. Sure, add the zinc, the C, D, B1, melatonin, cuercetin, etc … all good things, but perhaps not absolutely necessary, as the Bangladesh report didn’t mention a word about using any supplements or co-medications.

    Now we’ve got this study that uses 2-4 times the standard post-exposure/early infectious dosage (25ug/kg) taken daily, and then wants to add some kind of time release injection on top of that? Because taking a pill once a day is too complicated for people to remember? Or because getting a shot means going to a doctor, and thus puts money in the pocket of the medical community, whereas the pills are either distributed free in many countries, or for sale over the counter for a laughably small amount of money?

    I don’t see the point here. Looking forward to an explanation by one of your more learned commenters.

  2. I’m not in the medical field, but would injections be better for getting the medicine directly in the blood stream and maybe bypassing some stomach issues that some people have?

    Also, this is a small amount 25ug/kg = .025mg. The I-mask I believe uses 200ug/kg = .2mg. So this is just over 10% of their treatment dosage.

    1. Here in Brazil you can buy it without prescription. It is called here “ Ivermectina”. It is sold via internet by several drug stores, like Droga Raia, Panvel etc Good luck for us!

  3. Drew458 on December 22, 2020 at 7:01 am I agree with your comment. Taking a pill is easy enough. but I also think that the Ivermectin injectable mode is more appealing to the people who likes complicated stuff … by the way, here in Brazil there a lot of people using ivermectin. The latest prevention protocol involves getting ivermectin 2 days in a row each 2 weeks. “My protocol” is 1 dosage weekly, is easier to remember. Dosage? 3 capsules with 6 mg ( I weight 78 kg, 6 mg per 30 kg). My family is following the latest protocol for several months, no problems until now. MD Lucy Kerr leads a 570 medical doctors group trading patients with ivermectin successfully.